The Middle East conflict is now moving directly into pharma boardroom risk. Oil-market stress has intensified, with Vitol’s Bahrain chief warning that the market may still be underpricing the impact of disrupted Middle East supply, including a reported removal of nearly 14 million barrels per day from normal supply flows. Crude prices reportedly spiked as high as USD 126 per barrel after the conflict began, later cooling toward the mid-USD 90 range but still staying sharply above pre-crisis levels.
For pharma companies, this is not only an energy story. Reuters reported earlier that Middle East war disruption was affecting pharma air routes and creating risks for temperature-sensitive cancer medicines and other critical supplies. The risk is sharper for oncology drugs, biologics, vaccines, insulin products, injectables and cold-chain therapies because these products cannot tolerate casual delays.
The market impact is simple: large-cap pharma may remain defensive, but exporters, API traders, cold-chain suppliers and mid-sized formulation companies may face higher freight costs, longer delivery timelines, insurance pressure and inventory risk. In pharma, supply continuity is now becoming a valuation factor.
Witfire View: Pharma is no longer only a science business. In crisis periods, it becomes a logistics, inventory and trust business.
